AN2 Therapeutics, Inc. Common Stock ANTX
i
Market datapartial · fetched 2026-11-19T03:49:45.142Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-19T00:30:02.332758133Z
FundamentalsAlpha Vantage · unavailable
AN2 Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 3.38 | 800.0% | 72.6% | |||
| 25Δ | 8.30 | 800.0% | 118.6% | 3.78 | 800.0% | 65.9% |
| 30Δ | 7.65 | 800.0% | 105.3% | 4.17 | 800.0% | 59.1% |
| 35Δ | 7.07 | 800.0% | 93.5% | 4.57 | 800.0% | 52.3% |
| 40Δ | 4.97 | 800.0% | 45.6% | |||
| 45Δ | 5.35 | 800.0% | 39.0% | |||
| 50Δ | 5.73 | 800.0% | 32.4% | |||
| 55Δ | 6.13 | 797.4% | 25.5% | |||
| 60Δ | 6.55 | 788.8% | 17.7% | |||
| 65Δ | 6.98 | 780.2% | 10.0% | |||
| 70Δ | 7.16 | 718.3% | 8.1% | |||
| 75Δ | 7.32 | 653.4% | 6.6% | |||
| 80Δ | 7.49 | 588.5% | 5.1% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.38
- IV
- 800.0%
- B/E move
- 72.6%
25Δ
- Pseudo strike
- 8.30
- IV
- 800.0%
- B/E move
- 118.6%
- Pseudo strike
- 3.78
- IV
- 800.0%
- B/E move
- 65.9%
30Δ
- Pseudo strike
- 7.65
- IV
- 800.0%
- B/E move
- 105.3%
- Pseudo strike
- 4.17
- IV
- 800.0%
- B/E move
- 59.1%
35Δ
- Pseudo strike
- 7.07
- IV
- 800.0%
- B/E move
- 93.5%
- Pseudo strike
- 4.57
- IV
- 800.0%
- B/E move
- 52.3%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.97
- IV
- 800.0%
- B/E move
- 45.6%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.35
- IV
- 800.0%
- B/E move
- 39.0%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.73
- IV
- 800.0%
- B/E move
- 32.4%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.13
- IV
- 797.4%
- B/E move
- 25.5%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.55
- IV
- 788.8%
- B/E move
- 17.7%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.98
- IV
- 780.2%
- B/E move
- 10.0%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.16
- IV
- 718.3%
- B/E move
- 8.1%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.32
- IV
- 653.4%
- B/E move
- 6.6%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.49
- IV
- 588.5%
- B/E move
- 5.1%
Options history
History unavailable
Biotechnology
ARCT
Arcturus Therapeutics Holdings Inc., an RNA drug company, focuses on the treatment of liver and respiratory diseases. The company is headquartered in San Diego, California.
More →ARDX
Ardelyx, Inc., a biopharmaceutical company, develops and sells drugs for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company is…
More →ARGX
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The…
More →ARMP
Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of specific bacteriophage therapies for the treatment of antibiotic-resistant…
More →ARQT
Description unavailable
More →ARTV
Artiva Biotherapeutics, Inc. is a cutting-edge biotechnology firm dedicated to revolutionizing cancer therapy through its proprietary natural killer (NK) cell platform. With a…
More →